Intracellular Non Current Liabilities Total from 2010 to 2025

ITCI Stock  USD 127.82  0.24  0.19%   
Intracellular's Non Current Liabilities Total is increasing with slightly volatile movements from year to year. Non Current Liabilities Total is predicted to flatten to about 10 M. For the period between 2010 and 2025, Intracellular, Non Current Liabilities Total quarterly trend regression had mean deviation of  7,026,302 and range of 22 M. View All Fundamentals
 
Non Current Liabilities Total  
First Reported
2013-03-31
Previous Quarter
14.1 M
Current Value
13.5 M
Quarterly Volatility
8.9 M
 
Yuan Drop
 
Covid
Check Intracellular financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intracellular's main balance sheet or income statement drivers, such as Interest Expense of 8.9 M, Total Revenue of 560.7 M or Gross Profit of 520 M, as well as many indicators such as Price To Sales Ratio of 16.16, Dividend Yield of 0.0 or PTB Ratio of 7.67. Intracellular financial statements analysis is a perfect complement when working with Intracellular Valuation or Volatility modules.
  
Check out the analysis of Intracellular Correlation against competitors.

Latest Intracellular's Non Current Liabilities Total Growth Pattern

Below is the plot of the Non Current Liabilities Total of Intracellular Th over the last few years. It is Intracellular's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Intracellular's overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Total10 Years Trend
Slightly volatile
   Non Current Liabilities Total   
       Timeline  

Intracellular Non Current Liabilities Total Regression Statistics

Arithmetic Mean8,586,820
Geometric Mean5,310,103
Coefficient Of Variation91.64
Mean Deviation7,026,302
Median3,395,067
Standard Deviation7,869,235
Sample Variance61.9T
Range22M
R-Value0.73
Mean Square Error31.4T
R-Squared0.53
Significance0
Slope1,199,003
Total Sum of Squares928.9T

Intracellular Non Current Liabilities Total History

202510 M
202415.3 M
202313.3 M
202215.5 M
202118.7 M
202023.6 M
201920 M

About Intracellular Financial Statements

Investors use fundamental indicators, such as Intracellular's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Intracellular's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Non Current Liabilities Total15.3 M10 M

Currently Active Assets on Macroaxis

When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:
Check out the analysis of Intracellular Correlation against competitors.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.87)
Revenue Per Share
6.096
Quarterly Revenue Growth
0.39
Return On Assets
(0.07)
Return On Equity
(0.1)
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.